Next Article in Journal
Previous Article in Journal
Mar. Drugs 2005, 3(2), 64-73; doi:10.3390/md302064
Article

Verrucarin A Inhibition of MAP Kinase Activation in a PMA-stimulated Promyelocytic Leukemia Cell Line

1,* , 4, 4, 5, 3 and 2
Received: 4 March 2005; Accepted: 2 June 2005 / Published: 2 June 2005
View Full-Text   |   Download PDF [116 KB, uploaded 28 August 2008]   |   Browse Figures
Abstract: Verrucarin A is an inhibitor of protein synthesis. In this study, we examined the inhibitory action of verrucarin A on signal molecules. Verrucarin A partially inhibited the IL-8 production of a PMA-stimulated promyelocytic leukemia cell line (HL-60 cells), and the effect was related to the inhibition of NF-κB activation at noncytotoxic concentrations. Moreover, the inhibition of mitogen activated protein (MAP) kinase by verrucarin A was especially strong with p38- and JNK-phosphorylation. The findings show a new action of verrucarin A, and it is expected that this action relaxes the signal activation in response to stress.
Keywords: verrucarin A; MAP kinase; HL-60; p38-phosphorylation; JNKphosphorylation verrucarin A; MAP kinase; HL-60; p38-phosphorylation; JNKphosphorylation
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Oda, T.; Namikoshi, M.; Akano, K.; Kobayashi, H.; Honma, Y.; Kasahara, T. Verrucarin A Inhibition of MAP Kinase Activation in a PMA-stimulated Promyelocytic Leukemia Cell Line. Mar. Drugs 2005, 3, 64-73.

AMA Style

Oda T, Namikoshi M, Akano K, Kobayashi H, Honma Y, Kasahara T. Verrucarin A Inhibition of MAP Kinase Activation in a PMA-stimulated Promyelocytic Leukemia Cell Line. Marine Drugs. 2005; 3(2):64-73.

Chicago/Turabian Style

Oda, Taiko; Namikoshi, Michio; Akano, Kyoko; Kobayashi, Hisayoshi; Honma, Yoshio; Kasahara, Tadashi. 2005. "Verrucarin A Inhibition of MAP Kinase Activation in a PMA-stimulated Promyelocytic Leukemia Cell Line." Mar. Drugs 3, no. 2: 64-73.



Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert